Literature DB >> 18608861

Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach.

Wai M Liu1, Katherine A Scott, Jonathan Shamash, Simon Joel, Thomas B Powles.   

Abstract

Delta(9)-Tetrahydrocannabinol (THC) is the active metabolite of cannabis, which has demonstrable cytotoxic activity in vitro. In support of our previously published data, we have investigated the interactions between THC and anti-leukemia therapies and studied the role of the signalling pathways in mediating these effects. Results showed clear synergistic interactions between THC and the cytotoxic agents in leukemic cells. Additionally, exposure of cells to sub lethal levels of THC (1 microM) sensitised cells to these cytotoxic agents, by reducing IC(50) values by approximately 50%. Sensitisation appeared to be dependent upon the ability of THC to down regulate phosphorylated ERK, as cells dominantly expressive of MEK were not sensitised to the cytotoxic drugs by equi-molar amounts of THC. Overall, these results demonstrate for the first time that a combination approach with THC and established cytotoxic agents may enhance cell death in vitro. Additionally the MAPK/ERK pathway appears responsible in part for these effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18608861     DOI: 10.1080/10428190802239188

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

Review 1.  Pharmacological evidence of medicinal cannabis in oncology: a systematic review.

Authors:  Danielle Brown; Michael Watson; Janet Schloss
Journal:  Support Care Cancer       Date:  2019-05-06       Impact factor: 3.603

Review 2.  The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer.

Authors:  Magdalena Schab; Szymon Skoczen
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

3.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

4.  Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.

Authors:  W M Liu; D W Fowler; P Smith; A G Dalgleish
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

Review 5.  Anti-tumour actions of cannabinoids.

Authors:  Burkhard Hinz; Robert Ramer
Journal:  Br J Pharmacol       Date:  2018-08-07       Impact factor: 8.739

Review 6.  Cannabinoids as therapeutic agents in cancer: current status and future implications.

Authors:  Bandana Chakravarti; Janani Ravi; Ramesh K Ganju
Journal:  Oncotarget       Date:  2014-08-15

7.  Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.

Authors:  Massimo Nabissi; Maria Beatrice Morelli; Massimo Offidani; Consuelo Amantini; Silvia Gentili; Alessandra Soriani; Claudio Cardinali; Pietro Leoni; Giorgio Santoni
Journal:  Oncotarget       Date:  2016-11-22

Review 8.  The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology.

Authors:  Clara Andradas; Alexandra Truong; Jacob Byrne; Raelene Endersby
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

Review 9.  Cannabinoids as anticancer drugs: current status of preclinical research.

Authors:  Burkhard Hinz; Robert Ramer
Journal:  Br J Cancer       Date:  2022-03-11       Impact factor: 9.075

10.  Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis.

Authors:  John-Mark Fitzpatrick; Becky Hackett; Lisa Costelloe; William Hind; Eric J Downer
Journal:  Molecules       Date:  2022-03-08       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.